Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gentamycin + minocycline is a combination of two antibiotics, gentamicin (an aminoglycoside) and minocycline (a tetracycline derivative), used for their complementary antibacterial spectra. Gentamicin primarily targets gram-negative aerobic and facultative bacilli by binding to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death. Minocycline acts on both gram-positive and some gram-negative bacteria by also binding to the 30S ribosomal subunit but inhibits protein synthesis in a bacteriostatic manner. The combination has demonstrated synergistic effects against certain pathogens, particularly Escherichia coli and Clostridium species, making it potentially useful for mixed infections such as intra-abdominal sepsis where both aerobic/facultative and anaerobic organisms are present. No antagonism between these drugs has been observed at clinically relevant concentrations[1][2][6]. Additionally, preclinical studies suggest that minocycline may reduce gentamicin-induced ototoxicity[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gentamycin + minocycline.